Enliven Therapeutics (ELVN) Stock Forecast & Price Target
Score
Enliven Therapeutics, Inc. price target
| ELVN | |
|---|---|
| Low | $70.00 |
| Average | $76.29 |
| High | $82.00 |
| Upside vs current price | +56.3% |
The average target of $76.29 is +56.3% versus the current ELVN price of $48.80.
Enliven Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 3 |
| Buy | 11 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
14 analysts cover ELVN.
Enliven Therapeutics, Inc. EPS and revenue estimates
ELVN shows the next fiscal years with at least three analysts: 2026 EPS $-1.86, 2027 EPS $-2.27. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-1.86 | $10,000 |
| 2027 | $-2.27 | $5,000 |
Is Enliven Therapeutics, Inc. a buy or sell?
Of the 14 analysts covering Enliven Therapeutics, Inc., 14 rate it a buy (3 strong buy and 11 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The ELVN consensus label is Buy, beside 14 buy-side ratings and 0 sell-side ratings.
The average target of $76.29 implies +56.3% versus the current price of $48.80.
Those 14 ratings on ELVN are a headcount, and the label on file is Buy.
Reading the Enliven Therapeutics, Inc. forecast
The ELVN targets sit in a narrow band, from $70.00 to $82.00, around an average of $76.29.
Set next to the $48.80 ELVN quote, that average is +56.3%.
Ratings on the Enliven Therapeutics, Inc. cluster: 14 of 14 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
The average ELVN target over the last month is $73.00, below the $76.29 quarterly average.
Only 14 analysts cover ELVN, so the average rests on a short list.
Enliven Therapeutics, Inc. forecast questions
What is the ELVN price target?
The published range for ELVN is $70.00 to $82.00, with an average of $76.29. That average is +56.3% versus the current price of $48.80.
Is Enliven Therapeutics, Inc. a buy or sell?
Of the 14 analysts covering Enliven Therapeutics, Inc., 14 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the ELVN headcount is 14 buy, 0 hold, and 0 sell.
What is the EPS estimate for Enliven Therapeutics, Inc.?
Analyst EPS estimates for Enliven Therapeutics, Inc.: 2026 $-1.86, 2027 $-2.27.
What is the revenue estimate for Enliven Therapeutics, Inc.?
Analyst revenue estimates for Enliven Therapeutics, Inc.: 2026 $10,000, 2027 $5,000.
How many analysts cover ELVN?
14 analysts cover ELVN. Their consensus on ELVN is Buy, across those 14.